ConCallIQ
Go Pro
Home › Alkem Laboratories › Margin Trend

Alkem Laboratories Margin Trend — Quarter by Quarter

Alkem Laboratories's EBITDA margin moved from 21.9% in Q1 FY26 to 22.0% in Q3 FY26 across 3 quarters. Management commentary below explains the cost and pricing drivers mentioned on calls.

EBITDA Margin by Quarter

QuarterEBITDA Margin (%)YoY Change
Q3 FY2622.0%-35 bps
Q2 FY2623.0%—
Q1 FY2621.9%—

What management said about ebitda margin

G

Q3 FY26 · Occlutech EBITDA margin to reach 25% in 3-5 years

Occlutech's EBITDA margin is expected to improve from current ~4% to 25% in 3-5 years, driven by operating leverage and product mix.

G

Q2 FY26 · Full-year EBITDA margin guidance of 19.5-20%

Despite H2 opex from US CDMO (~₹50-60 cr/quarter) and GST impact (~₹50-60 cr), management expects EBITDA margin of 19.5-20% for FY26.

G

Q1 FY26 · FY26 EBITDA margin guidance maintained at ~19.5%

Management reiterated EBITDA margin guidance of 19-20% for FY26, despite strong Q1, citing potential H2 opex from CDMO and medtech ramp-up.